ASX Linkedin Twitter               

 

Scientific Presentations 2014

Presentation Title Conference Date
CALM study: A Phase II study of a novel oncolytic immunotherapeutic agent, Coxsackievirus A21, delivered intratumourally in patients with advanced malignant melanoma Society for Melanoma Research 2014 International Congress, Zurich  13-16 November 2014
Combination of a novel oncolytic immunotherapeutic agent, Coxsackievirus A21 and PD-1 or CTLA-4 blockade significantly reduces tumour growth in an immune competent mouse melanoma model The Society for Immunotherapy of Cancer Annual Meeting, Washington  6-9 November 2014
Combination of a novel oncolytic immunotherapeutic agent, Coxsackievirus A21 and PD-1 or CTLA-4 blockade significantly reduces tumour growth in an immune competent mouse melanoma model European Society for Medical Oncology, Madrid  26-30 September 2014
CALM Study: Secondary Endpoints of a Phase II study of a novel oncolytic immunotherapeutic agent, Coxsackievirus A21, delivered intratumorally in patients with advanced malignant melanoma European Society for Medical Oncology, Madrid  26-30 September 2014
CALM Study A Phase II study of an intratumourally delivered oncolytic immunotherapeutic agent (CVA21) in patients with stage IIIc and IV malignant melanoma American Society of Clinical Oncology, Chicago  30 May – 3 June 2014.
Major synergy between Coxsackievirus A21 (CAVATAKTM) and radiotherapy or chemotherapy in bladder cancer, due to up-regulation of viral receptors ICAM-1 & DAF The Eighth International Conference on Oncolytic Virus Therapeutics, Oxford, UK 9-13 April 2014.
Synergistic Activity of Coxsackievirus A21 (CVA21) and Docetaxel in Non-Small Cell Lung Cancer (NSCLC) The Eighth International Conference on Oncolytic Virus Therapeutics, Oxford, UK 9-13 April 2014.
Efficacy of CAVATAK against CD40L-stimulated CLL The Eighth International Conference on Oncolytic Virus Therapeutics, Oxford, UK 9-13 April 2014.
CAVATAK-mediated oncolytic immunotherapy in advanced melanoma patients American Association of Cancer Research Annual Meeting 5 – 9 April 2014
Viralytics Limited
Suite 305, Level 3, 66 Hunter Street
Sydney NSW 2000 Australia
T: +61 (0)2 9988 4000 F: +61 (0)2 8068 6038

© Viralytics Limited 2017
This information does not take your circumstances into account. Read the relevant ASX releases, financial reports and prospectuses before making an investment decision. Shares in Viralytics Limited, ABN 12 010 657 351, are traded on the Australian Stock Exchange (ASX:VLA) and on the over-the-counter market (OTC: VRACY).